In October 2017, DBV Technologies released top-line data from the first Phase III...
DBV’s Viaskin Peanut: still viable despite phase III failure
In October 2017, DBV Technologies released top-line data from the first Phase III trial of its highly awaited immunotherapeutic skin patch for peanut allergy—Viaskin Peanut.
Phase I Study of Bromodomain Inhibitor OTX015
This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma.
STYL’One Tableting Instruments, the Ultimate Time-Savers in R&D
As the name implies, the STYL'One Tableting Instrument is an instrument to make tablets. This generic name includes very different press types, from the simplest hand presses with no instrumentation to the most advanced research and development (R&D) presses such as the STYL'One, which is capable of mimicking high-speed production presses.
Gene-silencing therapy offers hope for Huntington’s disease
Ionis Pharmaceuticals’ IONIS-HTTRx is designed to address the cause of Huntington’s disease by reducing the production of the toxic mutant huntingtin protein responsible for this genetic neurodegenerative disorder.
Second Sartorius Research Xchange Forum Focuses on Regenerative Medicine and Cell Therapy
The latest Sartorius’ research forum Xchange focused on promoting interdisciplinary cooperation between science and industry in regards to regenerative medicine and cell therapy.
Migraine treatment to become less of a headache with revolutionary new solutions
On November 29, Amgen published the results from its Phase III trial, STRIVE, which evaluated the efficacy of its biologic molecule, erenumab, in the treatment of episodic migraine.
New NIH-funded consortium to expand trials for Alzheimer’s
The National Institute on Aging (NIA) at the National Institutes of Health (NIH) is funding new clinical trials consortium formed to enhance studies for treatments in Alzheimer’s disease and associated dementias.
NorthSea Therapeutics secures funding to develop NASH drug
Dutch biotech firm NorthSea Therapeutics has secured a €25m Series A funding to develop a structurally engineered fatty acid (SEFA), icosabutate, for treating non-alcoholic steatohepatitis (NASH).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.